A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: Sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis

International Journal of Hematology

Volumn 93, Issue 2, 2011, Pages 237-242

  Sakai, Katsuya ^a,b,c   Ishikawa, Yuichi ^b,c   Mori, Yumiko ^b,c   Kobayashi, Miki ^b   Iriyama, Chisako ^b   Ozawa, Yukiyasu ^b,c   Suzuki, Tatsuya ^b,c   Minami, Yosuke ^b   Ishikawa, Kazuhiro ^a   Kaneda, Norio ^a   Naoe, Tomoki ^b   Kiyoi, Hitoshi ^c  

^a MEIJO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BCR ABL mutation; CML; Resistance; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; ARGININE; BCR ABL PROTEIN; CYTARABINE; DASATINIB; ETOPOSIDE; GLUTAMIC ACID; GLYCINE; HISTIDINE; IMATINIB; IMMUNOGLOBULIN HEAVY CHAIN; LEUCINE; LYSINE; METHOTREXATE; MITOXANTRONE; PHENYLALANINE; TYROSINE;

ADULT; ALLELE; ARTICLE; BLAST CELL CRISIS; CASE REPORT; CELL CLONE; CHEMOSENSITIVITY; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; DRUG DOSE REDUCTION; EDEMA; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IN VITRO STUDY; MALE; PLEURA EFFUSION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RASH; SEQUENTIAL ANALYSIS; TREATMENT OUTCOME; WILD TYPE;

ANTINEOPLASTIC AGENTS; BLAST CRISIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 79952249328     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-011-0766-2     Document Type: Article

References (19)

1. R Hehlmann A Hochhaus M Baccarani 2007 Chronic myeloid leukaemia Lancet 370 342 350 1:CAS:528:DC%2BD2sXot1yltro%3D 10.1016/S0140-6736(07)61165-9 17662883 (Pubitemid 47094995)
2. BJ Druker F Guilhot SG O'Brien, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 1:CAS:528:DC%2BD28Xht12ntrzM 10.1056/NEJMoa062867 17151364 (Pubitemid 44903745)
3. JM Goldman 2007 How I treat chronic myeloid leukemia in the imatinib era Blood 110 2828 2837 1:CAS:528:DC%2BD2sXht1SmurfI 10.1182/blood-2007-04-038943 17626839 (Pubitemid 350006935)
4. D Marin D Milojkovic E Olavarria, et al. 2008 European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 4437 4444 1:CAS:528:DC%2BD1cXhsVCltbzF 10.1182/blood-2008-06-162388 18716134
5. Y Hirose H Kiyoi M Iwai T Yokozawa M Ito T Naoe 2002 Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis Int J Hematol 76 349 353 10.1007/BF02982695 12463599 (Pubitemid 43014099)
6. B Calabretta D Perrotti 2004 The biology of CML blast crisis Blood 103 4010 4022 1:CAS:528:DC%2BD2cXkvVyisb8%3D 10.1182/blood-2003-12-4111 14982876 (Pubitemid 38685338)
7. H Sakamaki K Ishizawa M Taniwaki, et al. 2009 Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia Int J Hematol 89 332 341 1:CAS:528:DC%2BD1MXkt1yhur0%3D 10.1007/s12185-009-0260-2 19263190
8. A Tojo K Usuki A Urabe, et al. 2009 A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph + CML or relapsed/refractory Ph+ ALL Int J Hematol 89 679 688 1:CAS:528: DC%2BD1MXms1Kks78%3D 10.1007/s12185-009-0327-0 19449194
9. JF Apperley 2007 Part II: management of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 1116 1128 1:CAS:528:DC%2BD2sXhsVWjurzP 10.1016/S1470-2045(07)70379-0 18054881 (Pubitemid 350182968)
10. A Quintas-Cardama H Kantarjian J Cortes 2009 Imatinib and beyond-exploring the full potential of targeted therapy for CML Nat Rev Clin Oncol 6 535 543 1:CAS:528:DC%2BD1MXhtVKjsrjP 10.1038/nrclinonc.2009.112 19652654
11. M Yanada J Takeuchi I Sugiura, et al. 2006 High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460 466 1:CAS:528: DC%2BD28XhsFSku7c%3D 10.1200/JCO.2005.03.2177 16344315 (Pubitemid 46630465)
12. H Kiyoi T Naoe K Horibe R Ohno 1992 Characterization of the immunoglobulin heavy chain complementarity determining region (CDR)-III sequences from human B cell precursor acute lymphoblastic leukemia cells J Clin Invest 89 739 746 1:CAS:528:DyaK38XhslajtL0%3D 10.1172/JCI115650 1541668
13. Y Ishikawa H Kiyoi A Tsujimura S Miyawaki Y Miyazaki K Kuriyama M Tomonaga T Naoe 2009 Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia Eur J Haematol 83 90 98 1:CAS:528:DC%2BD1MXpvFehs7o%3D 10.1111/j.1600-0609.2009.01261.x 19309322
14. SJ Zhang LY Ma QH Huang, et al. 2008 Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia Proc Natl Acad Sci USA 105 2076 2081 1:CAS:528:DC%2BD1cXitl2mu7Y%3D 10.1073/pnas.0711824105 18250304 (Pubitemid 351439467)
15. Y Ishikawa H Kiyoi K Watanabe, et al. 2010 Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study Cancer Sci 101 2186 2192 1:CAS:528:DC%2BC3cXhtlegtrnE 10.1111/j.1349-7006.2010.01643.x 20608939
16. S Hayette K Chabane A Tchirkov MG Berger FE Nicolini O Tournilhac 2009 Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia Haematologica 94 1324 1326 1:CAS:528:DC%2BD1MXhtlanurvO 10.3324/haematol.2009.007864 19734429
17. M Azam RR Latek GQ Daley 2003 Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 831 843 1:CAS:528:DC%2BD3sXivVWjsbY%3D 10.1016/S0092-8674(03)00190-9 12654249 (Pubitemid 36378885)
18. BA Burke M Carroll 2010 BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogenous leukemia Leukemia 24 1105 1112 1:CAS:528: DC%2BC3cXntFShs7w%3D 10.1038/leu.2010.67 20445577
19. L Klemm C Duy I Iacobucci, et al. 2009 The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia Cancer Cell 16 232 245 1:CAS:528:DC%2BD1MXhsVChs7vJ 10.1016/j.ccr.2009.07.030 19732723